Saturday, March 21, 2020 8:32:57 PM
HERTFORDSHIRE, England and PITTSBURGH, March 19, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its continued commitment to do its part in support of public health needs amidst the evolving COVID-19 pandemic. The company continues to focus its efforts on protecting our employees, producing critically needed medications, and turning our scientific and operational expertise towards identifying additional ways we may be able to assist in the massive prevention, diagnosis and treatment efforts needed to counter the spread of COVID-19.
For example, in the immediate term, Mylan has restarted production of hydroxychloroquine sulfate tablets at its West Virginia manufacturing facility in the U.S. to meet the potential for increased demand resulting from potential effectiveness of the product in treating COVID-19. Mylan's hydroxychloroquine sulfate tablets are approved by the U.S. Food and Drug Administration (FDA) for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. Although the product is not currently approved for use in the treatment of COVID-19, it is listed by the World Health Organization as a drug under investigation for efficacy against the coronavirus[1]. The company is also taking steps to initiate production of this product outside the U.S. in the coming weeks. We look forward to working with governments and health authorities globally to ensure patient access to this medicine as and where needed.
Mylan expects to be in a position to begin supplying product by mid-April, and with the active pharmaceutical ingredient that we currently have available, will be able to ramp up manufacturing to provide 50 million tablets to potentially treat a total of more than 1.5 million patients. The potential use of this medicine for COVID-19 related treatment is pending additional FDA and other regulatory body guidance
Recent VTRS News
- Viatris Announces the Pricing Terms of Maximum Tender Offer • PR Newswire (US) • 09/18/2024 03:30:00 PM
- Viatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer • PR Newswire (US) • 09/18/2024 12:45:00 AM
- Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024 • PR Newswire (US) • 09/16/2024 08:30:00 PM
- Viatris Announces Expiration and Results of Any and All Cash Tender Offers • PR Newswire (US) • 09/10/2024 11:00:00 PM
- Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers • PR Newswire (US) • 09/10/2024 03:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/04/2024 11:46:56 AM
- Viatris Announces Cash Tender Offers for Certain Outstanding Notes • PR Newswire (US) • 09/04/2024 07:30:00 AM
- Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress • PR Newswire (US) • 08/23/2024 10:59:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:03:07 PM
- Viatris Reports Second Quarter Financial Results for 2024 • PR Newswire (US) • 08/08/2024 10:59:00 AM
- Viatris Announces Second Quarter 2024 Dividend • PR Newswire (US) • 08/06/2024 10:59:00 AM
- Google Faces Antitrust Ruling; SunPower Files for Bankruptcy and Business Sale – Latest Business News • IH Market News • 08/06/2024 09:44:42 AM
- Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture • PR Newswire (US) • 07/03/2024 12:30:00 PM
- U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation • PR Newswire (US) • 07/02/2024 11:30:00 AM
- Viatris Named to TIME's World's Most Sustainable Companies 2024 List • PR Newswire (US) • 06/25/2024 03:00:00 PM
- Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024 • PR Newswire (US) • 06/07/2024 10:59:00 AM
- Viatris to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/04/2024 10:59:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 11:16:03 AM
- Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors • PR Newswire (US) • 06/03/2024 10:59:00 AM
- Viatris to Participate in the Jeffries Global Healthcare Conference • PR Newswire (US) • 05/31/2024 10:59:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 10:00:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:04:09 PM
- Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale • PR Newswire (US) • 05/21/2024 10:59:00 AM
- U.S. Index Futures Dip, Bank of England Holds Interest Rates at 5.25% • IH Market News • 05/09/2024 11:47:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:44:13 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM